Havana, May 1 - The Cuban vaccine candidate against COVID-19, Abdala, will complete this Saturday the administration of the third dose to all volunteers in phase III of clinical trials in the municipalities of Santiago de Cuba, Guantánamo and Bayamo.
An institutional tweet from the Center for Genetic Engineering and Biotechnology (CIGB), developer of Abdala, said this Friday that “The 1st. de Mayo concludes the administration Phase of the 3rd dose to the 48 thousand volunteers of the Phase III Clinical Trial of Abdala, in the municipalities of Santiago, Guantánamo and Bayamo. Thanks! "
The phase III clinical study began on March 22 in those three cities in southeastern Cuba. The application of the first dose to 48,290 subjects lasted six weeks and the second ended on April 17, with 47,620 volunteers, whose results were satisfactory.
When the volunteers are vaccinated, their follow-up will begin to evaluate the appearance of positive cases for the SARS-CoV-2 coronavirus, which causes COVID-19, Verena Muzio, director of Clinical Investigations at the CIGB, reported this week in a radio and television appearance.
Dr. Muzio emphasized that this will make it possible to compare the proportions between the vaccinated group and the placebo and thus evaluate the efficacy of the vaccine.
The CIGB is also in charge of the candidate vaccine via intranasal Mambisa, meanwhile, Sovereign 01 Sovereign Sovereign 02 and PLUS, are generated by the Institute Finlay Vaccine. (ACN)